These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32188385)

  • 21. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk: Is Imaging Helpful?
    Doumas SA; Tripathi S; Kashikar A; Khuttan A; Kumar A; Singh H; Canakis JP; Ashish K; Dey D; Oppenheim I; Dey AK
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102065. PubMed ID: 37652112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
    Vanni E; Marengo A; Mezzabotta L; Bugianesi E
    Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NAFLD and cardiovascular diseases: a clinical review.
    Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
    Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis.
    Zhou YY; Zhou XD; Wu SJ; Hu XQ; Tang B; Poucke SV; Pan XY; Wu WJ; Gu XM; Fu SW; Zheng MH
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):631-636. PubMed ID: 29351115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?
    Miptah HN; Ramli AS; Mohamad M; Hashim H; Tharek Z
    BMC Fam Pract; 2020 Nov; 21(1):238. PubMed ID: 33218301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.
    Lonardo A; Ballestri S; Guaraldi G; Nascimbeni F; Romagnoli D; Zona S; Targher G
    World J Gastroenterol; 2016 Nov; 22(44):9674-9693. PubMed ID: 27956792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
    Luo J; Xu L; Li J; Zhao S
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
    Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
    Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.
    Sharma D; Gotlieb N; Farkouh ME; Patel K; Xu W; Bhat M
    J Am Heart Assoc; 2022 Jan; 11(1):e022576. PubMed ID: 34927450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk factors in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
    Liver Int; 2019 Jan; 39(1):197-204. PubMed ID: 30253056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.
    Sánchez-Jiménez BA; Brizuela-Alcántara D; Ramos-Ostos MH; Alva-López LF; Uribe-Esquivel M; Chávez-Tapia NC
    Alcohol; 2018 Jun; 69():63-67. PubMed ID: 29660603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.
    Rix I; Steen Pedersen J; Storgaard H; Gluud LL
    Clin Physiol Funct Imaging; 2019 Mar; 39(2):122-127. PubMed ID: 29808958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
    Mann JP; Carter P; Armstrong MJ; Abdelaziz HK; Uppal H; Patel B; Chandran S; More R; Newsome PN; Potluri R
    PLoS One; 2020; 15(10):e0241357. PubMed ID: 33108366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Targher G; Byrne CD; Tilg H
    Gut; 2020 Sep; 69(9):1691-1705. PubMed ID: 32321858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification.
    Baratta F; D'Erasmo L; Bini S; Pastori D; Angelico F; Del Ben M; Arca M; Di Costanzo A
    Atherosclerosis; 2022 Sep; 357():51-59. PubMed ID: 36058083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
    Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Risk in Children with Nonalcoholic Fatty Liver Disease (NAFLD).
    Chociej AB; Wasilewska N; Flisiak-Jackiewicz M; Lebensztejn D
    Curr Pediatr Rev; 2020; 16(4):294-297. PubMed ID: 33038914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.